Histogen Inc. (HSTO): Price and Financial Metrics


Histogen Inc. (HSTO): $0.18

0.00 (-0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HSTO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HSTO Stock Summary

  • HSTO has a higher market value than only 1.37% of US stocks; more precisely, its current market capitalization is $13,386,657.
  • Revenue growth over the past 12 months for Histogen Inc comes in at -49.88%, a number that bests only 3.24% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for HSTO comes in at -204.5% -- higher than that of only 1.49% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Histogen Inc, a group of peers worth examining would be FKWL, GPL, SLS, SINT, and EMAN.
  • Visit HSTO's SEC page to see the company's official filings. To visit the company's web site, go to www.histogeninc.com.

HSTO Valuation Summary

  • HSTO's EV/EBIT ratio is -1; this is 103.41% lower than that of the median Healthcare stock.
  • Over the past 99 months, HSTO's price/sales ratio has gone NA NA.
  • Over the past 99 months, HSTO's price/earnings ratio has gone up 9.2.

Below are key valuation metrics over time for HSTO.

Stock Date P/S P/B P/E EV/EBIT
HSTO 2021-08-31 23.4 1.3 -2.2 -1.0
HSTO 2021-08-30 24.3 1.4 -2.3 -1.1
HSTO 2021-08-27 23.8 1.3 -2.3 -1.0
HSTO 2021-08-26 24.2 1.4 -2.3 -1.1
HSTO 2021-08-25 24.2 1.4 -2.3 -1.1
HSTO 2021-08-24 23.9 1.4 -2.3 -1.0

HSTO Growth Metrics

    Its year over year revenue growth rate is now at -89.71%.
  • Its 4 year cash and equivalents growth rate is now at -7.85%.
  • Its 2 year price growth rate is now at -90.17%.
HSTO's revenue has moved down $26,339,443 over the prior 52 months.

The table below shows HSTO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.032 -14.532 -14.95
2021-09-30 1.505 -15.888 -15.323
2021-06-30 1.409 -15.751 -14.731
2021-03-31 1.512 -13.012 -21.195
2020-12-31 2.059 -12.054 -18.769
2020-09-30 1.129 -9.962 -19.627

HSTO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HSTO has a Quality Grade of D, ranking ahead of 11.54% of graded US stocks.
  • HSTO's asset turnover comes in at 0.064 -- ranking 308th of 681 Pharmaceutical Products stocks.
  • PLXP, AGTC, and LPTX are the stocks whose asset turnover ratios are most correlated with HSTO.

The table below shows HSTO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.064 0.403 -1.400
2021-03-31 0.080 0.385 -2.095
2020-12-31 0.126 0.530 -2.520
2020-09-30 0.062 0.633 -4.218
2020-09-30 0.062 0.633 -4.218
2020-06-30 0.190 0.978 -6.396

HSTO Price Target

For more insight on analysts targets of HSTO, see our HSTO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.00 Average Broker Recommendation 1.25 (Strong Buy)

HSTO Stock Price Chart Interactive Chart >

Price chart for HSTO

HSTO Price/Volume Stats

Current price $0.18 52-week high $1.23
Prev. close $0.18 52-week low $0.15
Day low $0.18 Volume 691,300
Day high $0.19 Avg. volume 2,249,820
50-day MA $0.22 Dividend yield N/A
200-day MA $0.45 Market Cap 8.91M

Histogen Inc. (HSTO) Company Bio


Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.


HSTO Latest News Stream


Event/Time News Detail
Loading, please wait...

HSTO Latest Social Stream


Loading social stream, please wait...

View Full HSTO Social Stream

Latest HSTO News From Around the Web

Below are the latest news stories about Histogen Inc that investors may wish to consider to help them evaluate HSTO as an investment opportunity.

Histogen Announces Closing of $3.5 Million Private Placement

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, announced today the closing of its previously announced private placement for the issuance and sale of 8,235,297 shares of common stock and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock and associated warrant. The warrants have an exercise price of $0.425 per share of common stock and are exercisable commencing six months and one day following the date of issuance for a period of five and one-half years from the date of issuance.

Intrado Digital Media | December 21, 2021

Histogen Inc. (NASDAQ:HSTO) Sees Large Decline in Short Interest

Histogen Inc. (NASDAQ:HSTO) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 282,900 shares, a drop of 25.1% from the November 15th total of 377,900 shares. Approximately 0.7% of the companys stock are sold short. Based on an average trading volume of 457,300 []

Transcript Daily | December 19, 2021

Histogen Announces $3.5 Million Private Placement

SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, announced today that it has entered into securities purchase agreements with certain institutional and accredited investors to issue, in a private placement, 8,235,297 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock (or pre-funded warrant) and associated warrant, for expected gross proceeds to Histogen of approximately $3.5 million, before deducting placement agent fees and other...

Intrado Digital Media | December 16, 2021

Brokerages Expect Histogen Inc. (NASDAQ:HSTO) Will Post Earnings of -$0.11 Per Share

Wall Street analysts forecast that Histogen Inc. (NASDAQ:HSTO) will post earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Histogens earnings. Histogen reported earnings per share of ($0.26) during the same quarter last year, which would indicate a positive year-over-year growth rate of []

Dakota Financial News | December 12, 2021

Geode Capital Management LLC Acquires 149,336 Shares of Histogen Inc. (NASDAQ:HSTO)

Geode Capital Management LLC raised its holdings in Histogen Inc. (NASDAQ:HSTO) by 624.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,243 shares of the companys stock after buying an additional 149,336 shares during the period. Geode Capital Management LLCs holdings in Histogen were []

Dakota Financial News | December 1, 2021

Read More 'HSTO' Stories Here

HSTO Price Returns

1-mo -10.98%
3-mo -27.13%
6-mo -65.99%
1-year -82.00%
3-year -97.84%
5-year -99.65%
YTD -45.90%
2021 -56.11%
2020 -81.05%
2019 -76.88%
2018 -62.55%
2017 -12.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6656 seconds.